Xeris Biopharma Holdings, INC Form 4 insider transactions
NASDAQ
Xeris Biopharma Holdings, Inc. Director James Aloysius Brady sold 10,834 shares of common stock at a weighted average price of $5.5414 per share under a pre-arranged trading plan.
NASDAQ
Xeris Biopharma Holdings, Inc. President and COO Kevin McCulloch exercised stock options, acquiring 48,898 shares of common stock.
NASDAQ
Xeris Biopharma Holdings, Inc. Chief Financial Officer Steven Pieper exercised stock options to acquire 41,927 shares of common stock in a planned transaction.
NASDAQ
Xeris Biopharma Holdings, Inc.'s Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock through a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Xeris Biopharma Holdings, Inc.'s Chief Medical Officer, Anh Tu Nguyen, reported the withholding of 29,300 common shares for tax obligations related to vested restricted stock units.
NASDAQ
Xeris Biopharma Holdings CEO John Patrick Shannon Jr. reported the acquisition of restricted stock units and stock options, alongside tax-related share disposals.
NASDAQ
Xeris Biopharma's President and COO, Kevin McCulloch, reported recent equity grants and tax-related share dispositions.
NASDAQ
Xeris Biopharma's CFO, Steven Pieper, reported significant changes in his beneficial ownership, including new RSU grants and stock option acquisitions, alongside tax-related share disposals.
NASDAQ
Xeris Biopharma's Chief Medical Officer, Anh Tu Nguyen, was granted 121,293 restricted stock units and 162,162 stock options, aligning his interests with shareholders.
NASDAQ
Xeris Biopharma's Chief Legal Officer, Beth Hecht, reported the acquisition of restricted stock units and stock options, alongside sales and tax-related dispositions of common stock.
NASDAQ
Kevin McCulloch, President and COO of Xeris Biopharma Holdings, Inc., sold 15,000 shares of common stock at $8 per share through a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Xeris Biopharma Holdings CEO and Director, John Patrick Shannon Jr., sold 24,907 shares of common stock after exercising multiple stock options.
NASDAQ
Xeris Biopharma's Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock for a weighted average price of $7.4264 per share under a Rule 10b5-1 plan.
NASDAQ
A director at Xeris Biopharma Holdings, Inc. has filed a plan to sell 135,400 shares of common stock on December 19, 2025, at an average price of $7.2158.
NASDAQ
Xeris Biopharma Holdings, Inc. Director Barbara-Jean Anne Bormann-Kennedy sold 15,000 shares of common stock for approximately $7.09 per share under a Rule 10b5-1 plan.
NASDAQ
Xeris Biopharma Holdings, Inc.'s Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock for a weighted average price of $7.0067 per share under a Rule 10b5-1 trading plan.
NASDAQ
Xeris Biopharma Holdings, Inc. CEO and Director, John Patrick Shannon Jr., reported exercising stock options and selling common stock under a Rule 10b5-1 plan.
NASDAQ
Xeris Biopharma's Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock for a weighted average price of $7.3976 per share pursuant to a Rule 10b5-1 trading plan.
NASDAQ
Xeris Biopharma Holdings, Inc. President and COO Kevin McCulloch disposed of 733 shares of common stock to cover tax liabilities from vested restricted stock units.
NASDAQ
Xeris Biopharma Holdings, Inc. President and COO Kevin McCulloch's trust distributed 2,000 common shares to a beneficiary on September 11, 2025, with no sale occurring.
NASDAQ
Xeris Biopharma Holdings Director Marla Persky sold 15,500 shares of common stock at a weighted average price of $7.7168 per share under a Rule 10b5-1 trading plan.
NASDAQ
Xeris Biopharma Holdings, Inc. Director Jeffrey W. Sherman exercised stock options and subsequently sold a portion of the acquired shares.
NASDAQ
Xeris Biopharma Director John Johnson sold 107,500 shares of common stock for approximately $7.32 per share.
NASDAQ
Xeris Biopharma Director Dawn Halkuff sold 42,500 shares of common stock for approximately $309,000 on August 12, 2025, under a pre-planned Rule 10b5-1 program.
NASDAQ
Xeris Biopharma CEO John Patrick Shannon Jr. disposed of 36,918 shares to cover tax obligations related to restricted stock unit vesting.
NASDAQ
Xeris Biopharma's President and COO, Kevin McCulloch, reported routine stock transactions including shares withheld for taxes and an Employee Stock Purchase Plan acquisition.
NASDAQ
Xeris Biopharma Holdings, Inc.'s President and Chief Operating Officer, Kevin McCulloch, has acquired 25,000 shares of common stock, signaling increased insider confidence in the company.
NASDAQ
Form 4: Xeris Biopharma Director Awarded 50,000 Restricted Stock Units, Boosting Beneficial Ownership
Xeris Biopharma Holdings, Inc. director Barbara-Jean Anne Bormann-Kennedy was granted 50,000 restricted stock units, increasing her beneficial ownership to 157,500 shares.
NASDAQ
Xeris Biopharma Holdings, Inc. Director Marla Persky was granted 50,000 restricted stock units, aligning her interests with shareholders.
NASDAQ
Xeris Biopharma Holdings, Inc. Director Dawn Halkuff was awarded 50,000 restricted stock units, aligning her interests with shareholders and increasing her beneficial ownership.